Medindia

X

NIH Director Francis Collins and CF Foundation to Brief U.S. Senate on Advancing Disease Research

Wednesday, May 19, 2010 General News J E 4
Advertisement
Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies

BETHESDA, Md., May 19 /PRNewswire-USNewswire/ -- National Institutes of Health (NIH) Director Francis S. Collins, M.D., Ph.D., will lead a briefing on Capitol Hill Thursday, May 20, to discuss how funding for medical research at the NIH can be used more quickly to create new therapies for patients and save lives.

Since being appointed director of the NIH, Collins has stressed the importance of bridging the gap between basic research discoveries and the human testing of drugs. On average, it takes 15 years to translate scientific findings into viable therapies.

Collins created an NIH program -- Therapeutics for Rare and Neglected Diseases (TRND) -- and cites the drug development efforts of the Cystic Fibrosis Foundation as a model: "The CF Foundation has shown the way, has lit up the path... and what's been learned from CF can be extrapolated, generalized, to hundreds of other diseases."

Fifty years ago, people with cystic fibrosis, a fatal genetic disease, did not live long enough to attend grade school. Today there are more than 30 CF drugs in development and median life expectancy for someone with the disease is 37 years.

WHAT: How U.S. investments in medical research at the NIH can be leveraged to create new therapies for patients and save lives.

WHO:

WHEN: Thursday, May 20, 2010, 10:00 a.m. - 11:00 a.m.

WHERE: Dirksen Senate Office Building, G-11

-- Accelerating development of medical solutions for chronic diseases -- Highlighting lessons learned from other diseases, including CF -- Bridging the "Valley of Death" between science discoveries and the creation of new drugs

SOURCE Cystic Fibrosis Foundation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Centrifuge Systems & Saffron Technology Announce P...
S
MEDRAD and Pinestar Announce Data Integration to E...